Compare Enveric Biosciences Inc (ENVB) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while JPMorgan Diversified Return International Eqty ETF trades at $72.93 (market cap $378.77M). The key difference: JPMorgan Diversified Return International Eqty ETF is far larger — about 55.7× Enveric Biosciences Inc's market cap, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and JPMorgan Diversified Return International Eqty ETF for 120 Days on average.
| ENVB | JPIN | |
|---|---|---|
Market Cap | $6.80M | $378.77M |
Volume | 64,867 | 13,861 |
Sector | Health | — |
52-Week High | $10.80 | $77.80 |
52-Week Low | $1.27 | $64.96 |
Typical Hold Time | 14 Days | 120 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $72.94, down 0.42% on the day. Technical indicators are overwhelmingly bearish, with moving averages and oscillators signaling selling pressure, though RSI levels suggest potential oversold conditions. The ETF provides broad exposure to foreign large-cap value stocks, with a dividend scheduled for September 2026.
The outlook remains cautious due to weak technical momentum and lack of recent fundamental updates. Opportunities lie in international diversification and value exposure, but risks include global market volatility and ETF-specific underperformance. Investors should await fresh financial data for a clearer fundamental picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
